Roche Holding AG (SWX:ROG)
341.20
-10.30 (-2.93%)
At close: Mar 6, 2026
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
613.62K CHF
Profits / Employee
124.75K CHF
Market Cap
280.80B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novartis AG | 75,267 |
| Lonza Group AG | 19,771 |
| Alcon | 25,000 |
| Sandoz Group AG | 20,000 |
| Straumann Holding AG | 11,821 |
| Sonova Holding AG | 18,035 |
| Galenica AG | 7,991 |
| Ypsomed Holding AG | 2,000 |
Roche Holding AG News
- 2 hours ago - Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the 'weight loss Olympics' - CNBC
- 4 hours ago - New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus - GlobeNewsWire
- 4 hours ago - New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus - Business Wire
- 4 hours ago - New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus - Benzinga
- 4 hours ago - New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus - Benzinga
- 6 hours ago - Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly - Benzinga
- 10 hours ago - Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial - WSJ
- 15 hours ago - Roche's Petrelintide Achieves Over 100% Weight Loss In Phase 2 Trial - Nasdaq